ArticlePediatric nephrology (Berlin, Germany)2025
Long-term kidney side effects of allogeneic hematopoietic stem cell transplantation in children.
Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematopoietic stem cell transplantation (HSCT) is an effective treatment for various childhood diseases with long-term complications, including kidney side effects.
methodsWe conducted a single-center retrospective study of 213 patients who received allogeneic HSCT between February 2011 and December 2023. Patients were followed for at least 3 months post-HSCT, with a median follow-up of 2.9 years. We evaluated pre- and post-HSCT estimated glomerular filtration rate (eGFR) and kidney complications.
resultsAfter HSCT, patients showed significantly higher rates of acute kidney injury (21.6% vs. 4.1% pre-HSCT), hypertension (26.8% vs. 5.2% pre-HSCT), and tubulopathy (20.2% vs. 5.2% pre-HSCT). The median final eGFR was 144 mL/min/1.73 m
conclusionsHSCT can cause various kidney complications. GHF is common both before and after transplant, and eGFR often declines over time. UTIs, ATG conditioning, and inherited bone marrow failure syndromes are important risk factors for CKD. Individual factors and infection surveillance should be considered in these patients to approach kidney health.
Indexed as
Identifiers
40779169What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.